Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Speculative but powerful catalyst-driven setup: FDA's 2026-06-17 signal that AMT-130 Phase 1/2 data could support an accelerated approval filing materially improved the regulatory path, with a possible Q3 2026 BLA narrative. Shares are up about 99% over 21 trading days, confirming strong market interest.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong liquidity ⢠Persistent losses ⢠Equity dilution QURE has strong liquidity but remains a high-risk, richly valued investment due to persistent losses, leverage, dilution, and reliance on equity financing.
Price Behavior
Key Price Behavior Insights: ⢠Lower highs ⢠Support holding ⢠Resistance overhead Support Level: $42.50â$43.10 Resistance Level: $44.90â$46.00 QURE remains in a short-term downtrend over the last month, with $42.50â$43.10 support and a break above $46.00 needed to improve momentum.
Sentiment & News
Key News Insights: ⢠BLA submission ⢠U.K. expansion ⢠Approval catalyst uniQure's AMT-130 U.S. and U.K. regulatory filings, including a Priority Review request, position the stock for potential approval-driven upside despite execution risk.
AI Summary
QURE is now a high-expectations regulatory trade on AMT-130 rather than a distant platform biotech: its strong cash runway reduces financing risk, but the ~$2.8B valuation leaves little room for FDA skepticism of the small external-control data set, a narrow label, or weak reimbursementâmaking approval and launch economics the decisive catalysts.
Description
uniQure N.V. is a gene therapy company developing treatments for genetic and other severe diseases. Its lead program, etranacogene dezaparvovec (AMT-061), is in the Phase III HOPE-B trial for hemophilia B, and the broader pipeline includes clinical and preclinical candidates targeting central nervous system and neuromuscular disorders such as Huntingtonâs disease, Parkinsonâs disease, temporal lobe epilepsy, ALS and forms of Alzheimerâs, as well as earlier-stage hemophilia approaches. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jun 25 | Jul 2 | QURE | uniQure N.V. | Speculative but powerful catalyst-driven setup: FDA's 2026-06-17 signal that AMT-130 Phase 1/2 data could support an accelerated approval filing materially improved the regulatory path, with a possible Q3 2026 BLA narrative. Shares are up about 99% over 21 trading days, confirming strong market interest. | Closed | -14.8% |
| Jun 17 | Jun 24 | QURE | uniQure N.V. | Selected for a very strong near-term regulatory catalyst: on 2026-06-17 the FDA signaled AMT-130 mid-stage data could support an accelerated approval filing, with uniQure planning a BLA submission. The stock broke out sharply with about +94% 21-day momentum, making it a high-risk but catalyst-backed short-term momentum idea. | Closed | +1.4% |
| Sep 29 | Oct 6 | QURE | uniQure N.V. | uniQureâs Phase I/II Huntingtonâs gene therapy trial showed a 75% slowing of progression, triggering a 250% price surge and near five-year high. Strong FDA alignment for BLA filing and robust capital provide near-term growth catalysts despite technical overbought conditions and dilution risk. | Closed | -10.9% |